Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use
- PMID: 27772639
- DOI: 10.1053/j.ajkd.2016.05.026
Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use
Abstract
Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30% of patients, and the prevalence of hypertension is >85% in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150mmHg, and about 70%, 50%, and 40% use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7mmHg, whereas the nocturnal schedule reduced predialysis SBP by 7.3mmHg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21% to 47%. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.
Keywords: Antihypertensive medication; Frequent Hemodialysis Network; blood pressure; cardiovascular disease; chronic kidney disease; daily dialysis; end-stage renal disease (ESRD); fluid overload; home dialysis; hypertension; intensive hemodialysis; nocturnal hemodialysis; review; short daily hemodialysis; ultrafiltration.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Intensive Hemodialysis and Treatment Complications and Tolerability.Am J Kidney Dis. 2016 Nov;68(5S1):S43-S50. doi: 10.1053/j.ajkd.2016.05.021. Am J Kidney Dis. 2016. PMID: 27772642 Review.
-
Hemodialysis-associated hypertension: pathophysiology and therapy.Am J Kidney Dis. 2002 Feb;39(2):227-44. doi: 10.1053/ajkd.2002.30542. Am J Kidney Dis. 2002. PMID: 11840363 Review.
-
Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease.Am J Kidney Dis. 2016 Nov;68(5S1):S5-S14. doi: 10.1053/j.ajkd.2016.05.025. Am J Kidney Dis. 2016. PMID: 27772643 Review.
-
Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.Am J Kidney Dis. 2015 Aug;66(2):305-12. doi: 10.1053/j.ajkd.2015.01.018. Epub 2015 Mar 25. Am J Kidney Dis. 2015. PMID: 25818679 Clinical Trial.
-
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Am J Kidney Dis. 2016. PMID: 27772640 Review.
Cited by
-
The initial attempt at home hemodialysis in mainland China.BMC Nephrol. 2022 Dec 6;23(1):389. doi: 10.1186/s12882-022-03018-9. BMC Nephrol. 2022. PMID: 36474213 Free PMC article.
-
Interdialytic blood pressure variability and all-cause mortality in patients undergoing maintenance hemodialysis: a multicenter study using DialysisNet.Clin Exp Nephrol. 2025 Apr 23. doi: 10.1007/s10157-025-02674-z. Online ahead of print. Clin Exp Nephrol. 2025. PMID: 40268856
-
The effect of intensive hemodialysis on LVH regression and blood pressure control in ESRD patients.J Family Med Prim Care. 2020 Mar 26;9(3):1488-1491. doi: 10.4103/jfmpc.jfmpc_946_19. eCollection 2020 Mar. J Family Med Prim Care. 2020. PMID: 32509638 Free PMC article.
-
The Association between Intradialytic Hypertension and Metabolic Disorders in End Stage Renal Disease.Int J Hypertens. 2018 Apr 4;2018:1681056. doi: 10.1155/2018/1681056. eCollection 2018. Int J Hypertens. 2018. PMID: 29850223 Free PMC article.
-
Recurrent Intradialytic Hypotension, Associated Risk Factors, and Outcomes in Northern Tanzania: A Retrospective Cohort Study.Health Sci Rep. 2025 Apr 18;8(4):e70661. doi: 10.1002/hsr2.70661. eCollection 2025 Apr. Health Sci Rep. 2025. PMID: 40256139 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical